Please provide your email address to receive an email when new articles are posted on . People with cardiometabolic disorders who ate an overall and healthy plant-based diet had reduced risk for ...

We are pleased to announce the line-up of speakers for the next Bristol Synthesis Meeting, the largest one-day chemistry meeting in Europe. Having each made major impacts in their own particular ...

This review examines the associations between SCH and dyslipidemia, carotid intima-media thickness (C-IMT), cardiac dysfunction, and cardiovascular event risk. Evidence suggests SCH may exacerbate ...

Department of Biological Sciences, The University of Texas at Dallas, United States; Department of Urology, University of Texas Southwestern Medical Center, United States; ...

The PURSUIT trial sought to compare the placebo to the company’s first oral small molecule modulator, designed for the treatment of dyslipidemia, when used alongside lipid-lowering statin therapy, the ...

1,2 High LDL-C (≥70 mg/dL), a common type of dyslipidemia, is a key risk factor for atherosclerotic cardiovascular disease, including stroke and heart attack, and a significant public health concern.

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

The PROLONG-ANG3 trial showed that solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with statin-treated mixed dyslipidemia and was generally well tolerated.

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with ...

Background/Objectives: Dyslipidemia during adolescence has been associated with in-creased risk of cardiovascular disease throughout life; however, its prevalence and anthropometric predictors remain ...